title: [Comment. The role of regulatory agencies in the evaluation of drug safety: speaking about of selective serotonin receptor inhibitors].
authors.affiliation: División de Farmacoepidemiología y Farmacovigilancia, Agencia Española de Medicamentos y Productos Sanitarios, Madrid, España.
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: de Abajo
authors.forename: Dolores
authors.initials: D
authors.lastname: Montero
authors.forename: Gonzalo
authors.initials: G
authors.lastname: Calvo
mesh_terms: D000293:Adolescent; D016907:Adverse Drug Reaction Reporting Systems; D002648:Child; D017277:Drug Approval; D006801:Humans; D017374:Paroxetine / Q000009:adverse effects*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D013030:Spain
chemical_list: D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors